Skip to content

US · GOVX · BIOTECHNOLOGY

GeoVax Labs, Inc. (GOVX) intrinsic value and stock valuation

$1.81as of 2026-11-21 · Mkt cap 5.47M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

GeoVax Labs, Inc. DCF and intrinsic value

InvestorsCraft values GOVX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GOVX’s statements →

GeoVax Labs, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Smyrna, GA 30080 geovax.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2.49M+6.5% 5y CAGRd
20112025
Net income
-$-21.46M
20112025
Free cash flow
-$-21.5M
20112025
Total equity
$3.83M-16.7% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2.49M$3.95M$0.00$80K$390K
Operating income-$-21.64M-$-25.14M-$-26.74M-$-14.03M-$-18.75M
Net income-$-21.46M-$-24.99M-$-25.97M-$-14.02M-$-18.57M
EPSd-$-22.35M-$-119M-$-259.7M-$-140.2M-$-185.7M
Operating cash flow-$-21.47M-$-24.68M-$-25.17M-$-19.03M-$-11.2M
Capital expenditure-$-30K-$-20K-$-50K-$-130K-$-50K
Free cash flow-$-21.5M-$-24.7M-$-25.22M-$-19.16M-$-11.24M
Total assets$6.34M$8.16M$9.28M$31.4M$11.8M
Total debt$840K$0.00$0.00$0.00$0.00
Net debt-$-2.24M-$-5.51M-$-6.45M-$-27.61M-$-11.42M
Total equity$3.83M$5.05M$5.76M$26.6M$4.36M
Cash and short-term investments$3.09M$5.51M$6.45M$27.6M$11.4M
Income statement
20252024202320222021
Revenue$2.49M$3.95M$0.00$80K$390K
Cost of revenue$18.1M$100K$20.7M$9.12M$15.6M
Gross profit-$-15.63M$3.86M-$-20.72M-$-9.04M-$-15.17M
Research and development expenses$18.1M$23.7M$20.7M$9.12M$15.6M
Selling, general and administrative expenses$6.01M$5.39M$5.95M$4.99M$3.58M
Other expenses-$-18.12M-$-100K-$-20.65M-$-9.12M-$-15.55M
Operating expenses$6.01M$29M$6.02M$4.99M$3.58M
Cost and expenses$24.1M$29.1M$26.7M$14.1M$19.1M
Interest income$170K$170K$780K$10K$0.00
Interest expense$0.00$20K$0.00$0.00$0.00
Depreciation and amortization$70K$100K$70K$60K$40K
Ebitda-$-21.4M-$-24.88M-$-25.89M-$-13.96M-$-18.53M
Operating income-$-21.64M-$-25.14M-$-26.74M-$-14.03M-$-18.75M
Total other income/expenses, net$170K$150K$780K$10K$180K
Income before tax-$-21.46M-$-24.99M-$-25.97M-$-14.02M-$-18.57M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-21.46M-$-24.99M-$-25.97M-$-14.02M-$-18.57M
Weighted average shares outstanding$960K$210K$100K$100K$100K
Weighted average diluted shares outstanding$960K$210K$100K$100K$100K
Balance sheet
20252024202320222021
Cash and short-term investments$3.09M$5.51M$6.45M$27.6M$11.4M
Net receivables$0.00$660K$0.00$0.00$50K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$5.31M$7.93M$7.89M$28.9M$11.6M
Property, plant and equipment, net$940K$150K$210K$2.41M$160K
Goodwill and intangible assets$50K$60K$70K$80K$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.03M$220K$1.4M$2.41M$170K
Total assets$6.34M$8.16M$9.28M$31.4M$11.8M
Accounts payable$790K$1.85M$2.8M$1.75M$2.06M
Short-term debt$260K$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.94M$3.11M$3.52M$4.75M$5.44M
Long-term debt$580K$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$580K$0.00$0.00$0.00$2M
Capital lease obligations$840K$0.00$0.00$0.00$0.00
Total liabilities$2.52M$3.11M$3.52M$4.75M$7.43M
Common stock$0.00$10K$0.00$30K$10K
Retained earnings-$-150.82M-$-129.36M-$-104.36M-$-78.4M-$-64.38M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$3.83M$5.05M$5.76M$26.6M$4.36M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$840K$0.00$0.00$0.00$0.00
Net debt-$-2.24M-$-5.51M-$-6.45M-$-27.61M-$-11.42M
Cash flow statement
20252024202320222021
Net income-$-21.46M-$-24.99M-$-25.97M-$-14.02M-$-18.57M
Depreciation and amortization$70K$100K$70K$60K$40K
Stock-based compensation$0.00$530K$1.07M$900K$370K
Change in working capital-$-1.19M-$-310K-$-360K-$-5.97M$6.93M
Accounts receivable$660K-$-660K$0.00$50K$130K
Inventory$0.00$0.00$0.00-$-50K-$-130K
Accounts payable-$-1.47M-$-410K-$-1.23M-$-2.69M$6.81T
Net cash provided by operating activities-$-21.47M-$-24.68M-$-25.17M-$-19.03M-$-11.2M
Investments in property, plant and equipment-$-30K-$-20K-$-50K-$-130K-$-50K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-30K-$-20K-$-50K-$-130K-$-50K
Common stock issued$19.1M$21.4M$4.06M$27.7M$9.41M
Common stock repurchased$0.00$0.00$0.00$0.00-$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$19.1M$23.8M$4.06M$35.4M$12.8M
Net change in cash-$-2.42M-$-950K-$-21.16M$16.2M$1.54M
Cash at end of period$3.09M$5.51M$6.45M$27.6M$11.4M
Operating cash flow-$-21.47M-$-24.68M-$-25.17M-$-19.03M-$-11.2M
Capital expenditure-$-30K-$-20K-$-50K-$-130K-$-50K
Free cash flow-$-21.5M-$-24.7M-$-25.22M-$-19.16M-$-11.24M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About GeoVax Labs, Inc.

        GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.

        CEO
        David Alan Dodd
        Employees
        19
        Beta
        3.67

        Explore

        Frequently asked questions

        What is the intrinsic value of GeoVax Labs, Inc. (GOVX)?

        InvestorsCraft does not currently publish an intrinsic value for GOVX. How the IC value is calculated.

        Is GOVX undervalued?

        InvestorsCraft does not publish an undervaluation signal for GOVX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.